Portola Pharma (PTLA) Misses Q1 EPS by 9c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.91 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026